Clinical effect of add-on Primovist-enhanced magnetic resonance imaging on preoperative tumor staging in hepatocellular carcinoma patients

Young Joo Jin; Jin Woo Lee; Oh Sang Kwon; Young Kul Jung; Jung Hyun Kwon; Jeong Won Jang; Young Seok Kim; Tae Hun Kim; Yong Sun Jeon

doi:10.1002/jso.24272

Clinical effect of add-on Primovist-enhanced magnetic resonance imaging on preoperative tumor staging in hepatocellular carcinoma patients

Young Joo Jin, Jin Woo Lee, Oh Sang Kwon, Young Kul Jung, Jung Hyun Kwon, Jeong Won Jang, Young Seok Kim, Tae Hun Kim, Yong Sun Jeon

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Background/Aims: We analyzed the incidence of change of Barcelona Clinic Liver Cancer (BCLC) stage after add-on Primovist-enhanced magnetic resonance imaging (MRI) in hepatocellular carcinoma (HCC) patients with Barcelona Clinic Liver Cancer stage 0 or A as determined by liver dynamic computed tomography (LDCT). Methods: A total of 166 patients enrolled prospectively between August 2012 and December 2014 were retrospectively analyzed. The rates of stage change after Primovist-enhanced MRI and the treatment finally adopted in patients with stage change were evaluated. Results: Of the 166 patients, 24 (18.6%) had truly new HCCs. Forty-six (27.7%) and 120 (72.3%) patients had BCLC stages 0 and A, respectively, before Primovist-enhanced MRI, but after Primovist-enhanced MRI, 28 (16.9%), 134 (80.7%), and 4 (2.4%) patients had BCLC stages 0, A, and B, respectively. Tumor stage changed in 22 (13.3%) patients, from 0 to A (18, 39.1%) or A to B (4, 3.3%). Conclusions: Add-on Primovist-enhanced magnetic resonance imaging can change BCLC stage with 13.3% in patients with BCLC 0 or A staged HCC, as determined by LDCT. J. Surg. Oncol. 2016;114:106–111.

Original language	English
Pages (from-to)	106-111
Number of pages	6
Journal	Journal of Surgical Oncology
Volume	114
Issue number	1
DOIs	https://doi.org/10.1002/jso.24272
Publication status	Published - 2016 Jul 1

Keywords

Barcelona clinic liver cancer
hepatocellular carcinoma
liver dynamic computed tomography
primovist-enhanced magnetic resonance imaging

ASJC Scopus subject areas

Surgery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/jso.24272

Cite this

@article{c3a4ccda07294739baa7866c59e62c48,

title = "Clinical effect of add-on Primovist-enhanced magnetic resonance imaging on preoperative tumor staging in hepatocellular carcinoma patients",

abstract = "Background/Aims: We analyzed the incidence of change of Barcelona Clinic Liver Cancer (BCLC) stage after add-on Primovist-enhanced magnetic resonance imaging (MRI) in hepatocellular carcinoma (HCC) patients with Barcelona Clinic Liver Cancer stage 0 or A as determined by liver dynamic computed tomography (LDCT). Methods: A total of 166 patients enrolled prospectively between August 2012 and December 2014 were retrospectively analyzed. The rates of stage change after Primovist-enhanced MRI and the treatment finally adopted in patients with stage change were evaluated. Results: Of the 166 patients, 24 (18.6%) had truly new HCCs. Forty-six (27.7%) and 120 (72.3%) patients had BCLC stages 0 and A, respectively, before Primovist-enhanced MRI, but after Primovist-enhanced MRI, 28 (16.9%), 134 (80.7%), and 4 (2.4%) patients had BCLC stages 0, A, and B, respectively. Tumor stage changed in 22 (13.3%) patients, from 0 to A (18, 39.1%) or A to B (4, 3.3%). Conclusions: Add-on Primovist-enhanced magnetic resonance imaging can change BCLC stage with 13.3% in patients with BCLC 0 or A staged HCC, as determined by LDCT. J. Surg. Oncol. 2016;114:106–111.",

keywords = "Barcelona clinic liver cancer, hepatocellular carcinoma, liver dynamic computed tomography, primovist-enhanced magnetic resonance imaging",

author = "Jin, {Young Joo} and Lee, {Jin Woo} and Kwon, {Oh Sang} and Jung, {Young Kul} and Kwon, {Jung Hyun} and Jang, {Jeong Won} and Kim, {Young Seok} and Kim, {Tae Hun} and Jeon, {Yong Sun}",

note = "Publisher Copyright: {\textcopyright} 2016 Wiley Periodicals, Inc.",

year = "2016",

month = jul,

day = "1",

doi = "10.1002/jso.24272",

language = "English",

volume = "114",

pages = "106--111",

journal = "Journal of Surgical Oncology",

issn = "0022-4790",

publisher = "Wiley-Liss Inc.",

number = "1",

}

TY - JOUR

T1 - Clinical effect of add-on Primovist-enhanced magnetic resonance imaging on preoperative tumor staging in hepatocellular carcinoma patients

AU - Jin, Young Joo

AU - Lee, Jin Woo

AU - Kwon, Oh Sang

AU - Jung, Young Kul

AU - Kwon, Jung Hyun

AU - Jang, Jeong Won

AU - Kim, Young Seok

AU - Kim, Tae Hun

AU - Jeon, Yong Sun

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Background/Aims: We analyzed the incidence of change of Barcelona Clinic Liver Cancer (BCLC) stage after add-on Primovist-enhanced magnetic resonance imaging (MRI) in hepatocellular carcinoma (HCC) patients with Barcelona Clinic Liver Cancer stage 0 or A as determined by liver dynamic computed tomography (LDCT). Methods: A total of 166 patients enrolled prospectively between August 2012 and December 2014 were retrospectively analyzed. The rates of stage change after Primovist-enhanced MRI and the treatment finally adopted in patients with stage change were evaluated. Results: Of the 166 patients, 24 (18.6%) had truly new HCCs. Forty-six (27.7%) and 120 (72.3%) patients had BCLC stages 0 and A, respectively, before Primovist-enhanced MRI, but after Primovist-enhanced MRI, 28 (16.9%), 134 (80.7%), and 4 (2.4%) patients had BCLC stages 0, A, and B, respectively. Tumor stage changed in 22 (13.3%) patients, from 0 to A (18, 39.1%) or A to B (4, 3.3%). Conclusions: Add-on Primovist-enhanced magnetic resonance imaging can change BCLC stage with 13.3% in patients with BCLC 0 or A staged HCC, as determined by LDCT. J. Surg. Oncol. 2016;114:106–111.

AB - Background/Aims: We analyzed the incidence of change of Barcelona Clinic Liver Cancer (BCLC) stage after add-on Primovist-enhanced magnetic resonance imaging (MRI) in hepatocellular carcinoma (HCC) patients with Barcelona Clinic Liver Cancer stage 0 or A as determined by liver dynamic computed tomography (LDCT). Methods: A total of 166 patients enrolled prospectively between August 2012 and December 2014 were retrospectively analyzed. The rates of stage change after Primovist-enhanced MRI and the treatment finally adopted in patients with stage change were evaluated. Results: Of the 166 patients, 24 (18.6%) had truly new HCCs. Forty-six (27.7%) and 120 (72.3%) patients had BCLC stages 0 and A, respectively, before Primovist-enhanced MRI, but after Primovist-enhanced MRI, 28 (16.9%), 134 (80.7%), and 4 (2.4%) patients had BCLC stages 0, A, and B, respectively. Tumor stage changed in 22 (13.3%) patients, from 0 to A (18, 39.1%) or A to B (4, 3.3%). Conclusions: Add-on Primovist-enhanced magnetic resonance imaging can change BCLC stage with 13.3% in patients with BCLC 0 or A staged HCC, as determined by LDCT. J. Surg. Oncol. 2016;114:106–111.

KW - Barcelona clinic liver cancer

KW - hepatocellular carcinoma

KW - liver dynamic computed tomography

KW - primovist-enhanced magnetic resonance imaging

UR - http://www.scopus.com/inward/record.url?scp=84976587401&partnerID=8YFLogxK

U2 - 10.1002/jso.24272

DO - 10.1002/jso.24272

M3 - Article

C2 - 27332047

AN - SCOPUS:84976587401

SN - 0022-4790

VL - 114

SP - 106

EP - 111

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

IS - 1

ER -

Clinical effect of add-on Primovist-enhanced magnetic resonance imaging on preoperative tumor staging in hepatocellular carcinoma patients

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this